The role of Rebamipide ophthalmic suspension in management of dry eye disease (original) (raw)
Related papers
Role of 2% rebamipide ophthalmic suspension in the management of dry eye disease
IP innovative publication pvt. ltd, 2019
Objective: To study the therapeutic effects of 2% rebamipide ophthalmic suspension in dry eye disease. Materials and Methods: It was Prospective study of 80 patients diagnosed with dry eye syndrome from Jun 2016 to April 2017. After complete ophthalmic examination all were treated with 2% rebamipide suspension. Dry eye-related Symptom Score, anterior segment examination with slit lamp, Tear Film Break-Up Time, Fluorescein Ocular Surface Staining Score(FOS) & Schirmer test were used to collect data from patients at baseline & at 2, 4, 8 & 12 week visits. Results: Mean dry eye-related symptom score showed a significant improvement from baseline at 2, 4, 8 & 12 weeks (9.80, 7.20, 7.40 & 7.83 points). Median FOS also showed significant improvement from baseline (3.0 points) at 2, 4, 8 & 12 weeks (2.0, 2.0, 1.0 & 1.0 points respectively). TBUT & Schirmer test values also improved but were not significant after treatment. Conclusion: 2% rebamipide ophthalmic suspension is an effective in treating dry eye. It helps in improving both ocular & tear film stability.
IP Innovative Publication Pvt. Ltd. , 2018
Aim: To compare the efficacy of 2% rebamipide and 0.5% Carboxy methylcellulose (CMC) eye drops in dry eye patients. Materials and Methods: A 100 dry eye patients were enlisted and screened. Patients were allotted randomly into 2 groups- (Group-A) 2% rebamipide or (Group-B) 0.5% Carboxy methylcellulose (CMC) ophthalmic solution, after screening and instilled as 1 drop in each eye four times a day, for about two months. The signs and symptoms were assessed -at baseline, 2, 4, and at 8- week visits. The objective signs were –“Schirmer test and Tear film break-up time” (TBUT) while subjective symptoms were dry eye related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision. Results: A compelling improvement was noticed in the Schirmer test and TBUT values after the treatment in the 2% rebamipide group. The patients on 2% rebamipide eye drop showed considerable improvement in dry eye related ocular symptoms, than the patients on 0.5% CMC eye drop (51% and 29% respectively) at 2 months. Conclusions: 2% rebamipide ophthalmic solution was more efficient in improving both the subjective symptoms and objective signs of dry eye in comparison to the CMC group in this 8-week study. These findings showed that 2% rebamipide is the more effective drug for dry eye. Keywords: Carboxy methylcellulose, Dry eye, Efficacy, Rebamipide
Long-term Rebamipide and Diquafosol in Two Cases of Immune-Mediated Dry Eye
Optometry and vision science : official publication of the American Academy of Optometry, 2015
Two new drugs with mucin-inducing and secretion-promotive effects, rebamipide and diquafosol, were recently approved as topical dry-eye treatments. We report two cases in which the long-term use of mucin-inducing eye drops improved chronic ocular graft-versus-host disease (cGVHD)-related dry eye and ocular cicatricial pemphigoid (OCP)-like disease. Case 1. A 61-year-old woman had cGVHD-related dry eye that resisted traditional medications. Next, we use topical diquafosol in addition to conventional treatments. The patient used diquafosol for 6 months without experiencing any side effects. The symptoms, including dry-eye sensation, ocular pain, foreign body sensation, and photophobia, as well as ocular surface findings including fluorescein and rose bengal scores and tear break-up time (TBUT), partly improved. To further improve the clinical signs and symptoms and decrease chronic inflammation, rebamipide was added to diquafosol. The symptoms, TBUT, and fluorescein and rose bengal sc...